Climate Change Data

Cabaletta Bio, Inc.

Climate Impact & Sustainability Data (2022)

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Not disclosed

Environmental Achievements

  • Not disclosed

Social Achievements

  • Not disclosed

Governance Achievements

  • Not disclosed

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Report six-month clinical data from DSG3-CAART combination sub-study by the first half of 2024.
  • Report six-month clinical data from MuSK-CAART combination cohort by the first half of 2024.
  • Initial clinical data from CABA-201 by the first half of 2024.
Short-term Goals:
  • Report one-month safety and persistence data from DSG3-CAART combination sub-study in the first half of 2023.
  • Potential IND clearance of CABA-201 in the first half of 2023.

Environmental Challenges

  • Limited operating history and significant losses since inception.
  • Dependence on University of Pennsylvania for research, development, and manufacturing.
  • Reliance on intellectual property licensed from Penn and IASO.
  • Need to raise substantial additional funding.
  • Difficulties enrolling patients in clinical trials.
  • Complex manufacturing process.
  • Substantial competition.
  • Potential need to establish own manufacturing facility.
  • Retaining key employees.
Mitigation Strategies
  • Three-stage manufacturing plan leveraging academic partners, CMOs, and ultimately, own facilities.
  • Collaboration with WuXi Advanced Therapies for cell processing and Oxford Biomedica for lentiviral vectors.
  • Exclusive translational research partnership with Dr. Georg Schett.
  • Focus on protecting intellectual property.
  • Experienced management team with demonstrated success in cell therapy development and manufacturing.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Not disclosed